Haisco Pharmaceutical Group Co., Ltd. (SHE: 002653) announced, via listing on the website of China’s Center for Drug Evaluation (CDE) of the NMPA, that its Class 1 investigational new drug HSK42360‑Na tablets has been proposed for inclusion in the Breakthrough Therapy program, targeting BRAF V600‑mutant recurrent or progressive high‑grade glioma. In June 2026, Haisco licensed the asset’s overseas rights to US‑based Nuvectis Pharma.
Regulatory Milestone
| Item | Detail |
|---|---|
| Agency | CDE, NMPA (China) |
| Designation Type | Proposed for Breakthrough Therapy Designation (BTD) |
| Product | HSK42360‑Na Tablets, Class 1 new drug |
| Indication | BRAF V600‑mutant recurrent or progressive high‑grade glioma |
| Listing Date | 17 Sep 2026 |
| Next Steps | Public notice period, followed by formal BTD inclusion with intensified CDE communication and review support |
Drug Profile & Mechanism of Action
- Molecule: HSK42360, independently developed by Haisco as a BRAF “paradoxical breaker” inhibitor.
- Dual Mechanism: Simultaneously inhibits BRAF V600X mutations and blocks BRAF dimer formation – the dimerization‑driven reactivation pathway through which tumors escape first‑generation agents.
- Innovation: Designed to overcome acquired resistance observed with first‑generation BRAF inhibitors across multiple tumor types, a core limitation of the current BRAF‑targeted standard of care.
- CNS Penetration: The molecule demonstrates favorable central nervous system penetrance, supporting potential therapeutic advantage in both primary brain tumors and brain metastases.
- Global Rights: Ex‑Greater China development, manufacturing, and commercialization rights licensed to Nuvectis Pharma (US).
Clinical Development Landscape
| Program | Population / Regimen | Objective | Data Status |
|---|---|---|---|
| HSK42360‑Na (BTD indication) | BRAF V600‑mutant recurrent or progressive high‑grade glioma | Basis of the proposed Breakthrough Therapy Designation | Not disclosed |
| Phase I/II trial (CTR20262782) | BRAF V600‑mutant metastatic colorectal cancer (mCRC) | HSK42360‑Na + cetuximab ± chemotherapy – safety, tolerability, and efficacy | Ongoing |
The concurrent combination strategy in mCRC – pairing the paradoxical breaker with anti‑EGFR therapy, with or without chemotherapy – mirrors the established clinical logic of vertical pathway blockade in BRAF V600‑mutant colorectal tumors and signals Haisco’s intent to develop HSK42360 as a multi‑tumor BRAF franchise.
Market Impact & Outlook
- Glioma Landscape: BRAF V600‑mutant high‑grade glioma is a rare, aggressive CNS malignancy with high unmet need, where CNS‑penetrant targeted therapy is a decisive differentiator; BTD status would accelerate Haisco’s China development and review pathway.
- Resistance‑Breaking Edge: By inhibiting mutant BRAF while blocking dimer formation, HSK42360 is positioned against the acquired‑resistance liability of first‑generation BRAF inhibitors, potentially extending durability of response across glioma, mCRC, and other BRAF‑driven tumors.
- Nuvectis Deal Economics: Haisco receives a US$40 million upfront and near‑term milestone payment, up to US$1.421 billion in additional clinical, regulatory, and commercial milestones, plus tiered royalties of up to double digits on future net product sales.
- Pipeline Synergy: The same transaction grants Nuvectis exclusive ex‑Greater China/Southeast Asia/India rights to HSK39297 (Sipucotan), Haisco’s selective complement factor B (CFB) inhibitor, which was approved in China in July 2026 for paroxysmal nocturnal hemoglobinuria (PNH) – underscoring the breadth of Haisco’s internationally partnered pipeline.
- Strategic Positioning: Concurrent CNS oncology designation, a global licensing deal, and a launched complement franchise mark an inflection point for Haisco’s transition toward a globally out‑licensed innovative‑drug model.
Forward‑Looking Statements
This brief contains forward‑looking statements regarding regulatory timelines, Breakthrough Therapy Designation finalization, clinical outcomes, milestone achievement, and commercial expectations for HSK42360 and HSK39297. Actual results may differ materially due to risks including final CDE designation decisions, trial readouts, licensing milestone conditions, and market competition. A proposed BTD listing does not constitute formal designation or any marketing authorization.-Fineline Info & Tech
